- Hemostemix (HEM) has completed its Phase II clinical trial subject follow up, as the final subject completed their last follow-up visit
- The company is shifting its focus to completing data analyses and reporting associated with finalizing the Phase II clinical trial
- Hemostemix developed and is commercializing its lead product ACP-01 for treatment of several conditions
- ACP-01 has been used to treat over 300 patients, and is the subject of a randomized, placebo-controlled, double blind trial
- Hemostemix is unchanged on the day, with shares of the company trading at C$0.35 at 3:46 pm ET
Hemostemix (HEM) has completed its Phase II clinical trial subject follow-up, as the final subject completed their last follow-up visit.
With subject follow up now finished, the company is shifting its focus to completing the data analyses and reporting associated with finalizing the Phase II clinical trial.
Hemostemix developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
ACP-01 has been used to treat over 300 patients and is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On October 21, 2019, the company announced the results from its Phase II CLI trial abstract which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years.
Hemostemix is a publicly-traded autologous stem cell therapy company and winner of the World Economic Forum Technology Pioneer Award.
Hemostemix is unchanged on the day, with shares of the company trading at C$0.35 at 3:46 pm ET.
